Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4002 (HPN217) in relapsed/refractory multiple myeloma
NCT04184050Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2020
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Nanobodies (VHH)
- Countries
- 3
01
Overview
Phase 1, open-label trial of HPN217 in multiple myeloma (MM) (2 arms), sponsored by Merck & Co. Primary endpoints: Treatment-emergent Adverse Events at 6 years, Discontinuation Due to Adverse Events at 6 years and 15 more. Started Apr 2020; status: active, not recruiting.
02
Drugs
HPN217
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04184050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184050.